Chronic kidney disease (CKD) is a common diabetes-related complication among type 2 diabetes (T2DM) patients, with a high prevelance within primary care settings. In this touchENDOCRINOLOGY interview, we speak with Dr Sara (Mandy) Reece (Philadelphia College of Osteopathic Medicine (PCOM), Georgia School of Pharmacy, Suwanee, GA, USA) to discuss the newly approved medications to mitigate kidney risk in people with T2DM and CKD. Dr Reece also discusses current guidelines for the treatment of CKD in T2D and discusses the role of the DCES in optimizing CKD outcomes.
The abstract entitled: ‘Chronic Kidney Disease in Type 2 Diabetes: An Update for the Diabetes Care and Education Specialist‘ was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022
Questions:
- What is known about the incidence and risk of chronic kidney disease (CKD) in people with type 2 diabetes (T2D)? (0:37)
- Could you give us a brief overview of recently approved medications to mitigate kidney risk in people with T2D and CKD? (1:10)
- What factors should be considered when deciding which drug to prescribe to reduce the risk of kidney function decline in T2D patients? (4:29)
- Could you tell us a little about the current guidelines for the treatment of CKD in T2D? (6:27)
- Â What is the role of the diabetes care & education specialists in optimising CKD outcomes? (8:25)
Disclosures: TBC
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Filmed as a highlight of ADCES 2022
Click here for more related content.
